FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149579095> ?p ?o ?g. }

• W2149579095 endingPage "418" @default.
• W2149579095 startingPage "407" @default.
• W2149579095 abstract "To determine whether differences in baseline lesion size and visual acuity might explain differing results found in three different lesion compositions (predominantly classic, minimally classic, and occult with no classic) among three placebo-controlled, randomized clinical trials evaluating photodynamic therapy with verteporfin (Visudyne, Novartis AG), also termed verteporfin therapy, in patients with subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).Exploratory analyses were conducted in patients with predominantly classic or minimally classic lesions at enrollment in the Treatment of AMD with Photodynamic Therapy (TAP) Investigation and in AMD patients with occult with no classic CNV in the Verteporfin In Photodynamic Therapy (VIP) Trial. Baseline characteristics of patients among these three lesion compositions were compared. In addition, multiple linear regression modeling was used to explore the effect of baseline lesion size, visual acuity, and lesion composition on mean change in visual acuity from baseline to 24 months.At baseline, the mean size of predominantly classic lesions (3.4 disk areas) was smaller than that of minimally classic (4.7 disk areas) and occult with no classic lesions (4.3 disk areas). In the multiple linear regression model of individual lesion compositions, there was a significant treatment-by-lesion-size interaction for minimally classic and occult with no classic lesions, but not for predominantly classic lesions. Interaction between treatment and baseline visual acuity was not significant for any lesion composition. Small verteporfin-treated lesions lost less vision than large verteporfin-treated lesions in each lesion composition. In the multiple linear regression model that included all lesion compositions, lesion size was a more significant predictive factor for the magnitude of treatment benefit than either lesion composition or visual acuity. Smaller (4.0 disk areas or less) minimally classic and occult with no classic lesions had similar visual acuity outcomes to those observed in predominantly classic lesions.Based on exploratory analyses, lesion size in the TAP Investigation and VIP Trial was an important predictor of the magnitude of treatment benefit with verteporfin therapy in occult with no classic and minimally classic lesion compositions. In patients with AMD, treating smaller rather than larger neovascular lesions, regardless of lesion composition, likely will result in a better level of visual acuity." @default.
• W2149579095 created "2016-06-24" @default.
• W2149579095 creator A5002723940 @default.
• W2149579095 creator A5004279704 @default.
• W2149579095 creator A5012217069 @default.
• W2149579095 creator A5015954067 @default.
• W2149579095 creator A5018009341 @default.
• W2149579095 creator A5028345280 @default.
• W2149579095 creator A5041901490 @default.
• W2149579095 creator A5053656307 @default.
• W2149579095 creator A5061226923 @default.
• W2149579095 creator A5068100425 @default.
• W2149579095 creator A5068578027 @default.
• W2149579095 creator A5068824948 @default.
• W2149579095 creator A5074264859 @default.
• W2149579095 creator A5077898938 @default.
• W2149579095 creator A5079526133 @default.
• W2149579095 creator A5079689893 @default.
• W2149579095 creator A5084054147 @default.
• W2149579095 date "2003-09-01" @default.
• W2149579095 modified "2023-09-26" @default.
• W2149579095 title "Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1" @default.
• W2149579095 cites W1521704129 @default.
• W2149579095 cites W1601975653 @default.
• W2149579095 cites W2150533138 @default.
• W2149579095 cites W2157389251 @default.
• W2149579095 cites W233579014 @default.
• W2149579095 cites W4213290870 @default.
• W2149579095 cites W945208301 @default.
• W2149579095 doi "https://doi.org/10.1016/s0002-9394(03)00223-x" @default.
• W2149579095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12967792" @default.
• W2149579095 hasPublicationYear "2003" @default.
• W2149579095 type Work @default.
• W2149579095 sameAs 2149579095 @default.
• W2149579095 citedByCount "259" @default.
• W2149579095 countsByYear W21495790952012 @default.
• W2149579095 countsByYear W21495790952013 @default.
• W2149579095 countsByYear W21495790952014 @default.
• W2149579095 countsByYear W21495790952015 @default.
• W2149579095 countsByYear W21495790952016 @default.
• W2149579095 countsByYear W21495790952017 @default.
• W2149579095 countsByYear W21495790952018 @default.
• W2149579095 countsByYear W21495790952019 @default.
• W2149579095 countsByYear W21495790952020 @default.
• W2149579095 countsByYear W21495790952021 @default.
• W2149579095 countsByYear W21495790952022 @default.
• W2149579095 countsByYear W21495790952023 @default.
• W2149579095 crossrefType "journal-article" @default.
• W2149579095 hasAuthorship W2149579095A5002723940 @default.
• W2149579095 hasAuthorship W2149579095A5004279704 @default.
• W2149579095 hasAuthorship W2149579095A5012217069 @default.
• W2149579095 hasAuthorship W2149579095A5015954067 @default.
• W2149579095 hasAuthorship W2149579095A5018009341 @default.
• W2149579095 hasAuthorship W2149579095A5028345280 @default.
• W2149579095 hasAuthorship W2149579095A5041901490 @default.
• W2149579095 hasAuthorship W2149579095A5053656307 @default.
• W2149579095 hasAuthorship W2149579095A5061226923 @default.
• W2149579095 hasAuthorship W2149579095A5068100425 @default.
• W2149579095 hasAuthorship W2149579095A5068578027 @default.
• W2149579095 hasAuthorship W2149579095A5068824948 @default.
• W2149579095 hasAuthorship W2149579095A5074264859 @default.
• W2149579095 hasAuthorship W2149579095A5077898938 @default.
• W2149579095 hasAuthorship W2149579095A5079526133 @default.
• W2149579095 hasAuthorship W2149579095A5079689893 @default.
• W2149579095 hasAuthorship W2149579095A5084054147 @default.
• W2149579095 hasConcept C118487528 @default.
• W2149579095 hasConcept C141071460 @default.
• W2149579095 hasConcept C142724271 @default.
• W2149579095 hasConcept C204787440 @default.
• W2149579095 hasConcept C2776403814 @default.
• W2149579095 hasConcept C2778257484 @default.
• W2149579095 hasConcept C2781148688 @default.
• W2149579095 hasConcept C2781156865 @default.
• W2149579095 hasConcept C2781359195 @default.
• W2149579095 hasConcept C520017518 @default.
• W2149579095 hasConcept C71924100 @default.
• W2149579095 hasConceptScore W2149579095C118487528 @default.
• W2149579095 hasConceptScore W2149579095C141071460 @default.
• W2149579095 hasConceptScore W2149579095C142724271 @default.
• W2149579095 hasConceptScore W2149579095C204787440 @default.
• W2149579095 hasConceptScore W2149579095C2776403814 @default.
• W2149579095 hasConceptScore W2149579095C2778257484 @default.
• W2149579095 hasConceptScore W2149579095C2781148688 @default.
• W2149579095 hasConceptScore W2149579095C2781156865 @default.
• W2149579095 hasConceptScore W2149579095C2781359195 @default.
• W2149579095 hasConceptScore W2149579095C520017518 @default.
• W2149579095 hasConceptScore W2149579095C71924100 @default.
• W2149579095 hasIssue "3" @default.
• W2149579095 hasLocation W21495790951 @default.
• W2149579095 hasLocation W21495790952 @default.
• W2149579095 hasOpenAccess W2149579095 @default.
• W2149579095 hasPrimaryLocation W21495790951 @default.
• W2149579095 hasRelatedWork W1491606239 @default.
• W2149579095 hasRelatedWork W1615644543 @default.
• W2149579095 hasRelatedWork W1979874741 @default.
• W2149579095 hasRelatedWork W1991009668 @default.
• W2149579095 hasRelatedWork W2012546470 @default.
• W2149579095 hasRelatedWork W2029111837 @default.

• next